|
|||
|
DRUGS & SUPPLEMENTS
|
Active ingredient: Mepivacaine Hydrochloride
What are the side effects you encounter while taking this medicine? |
Mepivacaine Hydrochloride uses
- Indications and usage:
- Contraindications:
- Warnings:
- Precautions:
- Adverse reactions:
- Overdosage:
- Dosage and administration:
- How supplied:
INDICATIONS AND USAGE:
Mepivacaine Hydrochloride (Mepivacaine HCl Injection, USP), is indicated for production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
The routes of administration and indicated concentrations for mepivacaine are:
local infiltration 0.5% (via dilution) or 1%
| peripheral nerve blocks | 1% and 2% |
| epidural block | 1%, 1.5%, 2% |
| caudal block | 1%, 1.5%, 2% |
See DOSAGE AND ADMINISTRATION for additional information. Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of mepivacaine.
CONTRAINDICATIONS:
Mepivacaine is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type or to other components of mepivacaine solutions.
WARNINGS:
LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER INSURING THE
Local anesthetic solutions containing antimicrobial preservatives (ie, those supplied in multiple-dose vials) should not be used for epidural or caudal anesthesia because safety has
It is essential that aspiration for blood or cerebrospinal fluid (where applicable) be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative aspiration does not ensure against an intravascular or subarachnoid injection.
Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics.
Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result.
Local anesthetic procedures should be used with caution when there is inflammation and/or sepsis in the region of the proposed injection.
Mixing or the prior or intercurrent use of any local anesthetic with mepivacaine cannot be recommended because of insufficient data on the clinical use of such mixtures.
PRECAUTIONS:
General
The safety and effectiveness of local anesthetics depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. During major regional nerve blocks, the patient should have IV fluids running via an indwelling catheter to assure a functioning intravenous pathway. The lowest dosage of local anesthetic that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. Injections should be made slowly, with frequent aspirations before and during the injection to avoid intravascular injection. Current opinion favors fractional administration with constant attention to the patient, rather than rapid bolus injection. Syringe aspirations should also be performed before and during each supplemental injection in continuous (intermittent) catheter techniques. An intravascular injection is still possible even if aspirations for blood are negative.
During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and the effects monitored before the full dose is given. When using a “continuous” catheter technique, test doses should be given prior to both the original and all reinforcing doses, because plastic tubing in the epidural space can migrate into a blood vessel or through the dura. When the clinical conditions permit, an effective test dose should contain epinephrine (10 mcg to 15 mcg have been suggested) to serve as a warning of unintended intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce an “epinephrine response” within 45 seconds, consisting of an increase of pulse and blood pressure, circumoral pallor, palpitations, and nervousness in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Therefore, following the test dose, the heart rate should be monitored for a heart rate increase. The test dose should also contain 45 mg to 50 mg of Mepivacaine Hydrochloride to detect an unintended intrathecal administration. This will be evidenced within a few minutes by signs of spinal block (eg, decreased sensation of the buttocks, paresis of the legs, or, in the sedated patient, absent knee jerk).
Injection of repeated doses of local anesthetics may cause significant increases in plasma levels with each repeated dose due to slow accumulation of the drug or its metabolites or to slow metabolic degradation. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients, and acutely ill patients should be given reduced doses commensurate with their age and physical status. Local anesthetics should also be used with caution in patients with severe disturbances of cardiac rhythm, shock, heart block, or hypotension.
Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs, and the patient’s state of consciousness should be performed after each local anesthetic injection. It should be kept in mind at such times that restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, depression, or drowsiness may be early warning signs of central nervous system toxicity.
Local anesthetic solutions containing a vasoconstrictor should be used cautiously and in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply such as digits, nose, external ear, penis. Patients with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. Ischemic injury or necrosis may result.
Mepivacaine should be used with caution in patients with known allergies and sensitivities.
Because amide-type local anesthetics such as mepivacaine are metabolized by the liver and excreted by the kidneys, these drugs, especially repeat doses, should be used cautiously in patients with hepatic and renal disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations. Local anesthetics should also be used with caution in patients with impaired cardiovascular function because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.
Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are employed in patients during or following the administration of potent inhalation anesthetics. In deciding whether to use these products concurrently in the same patient, the combined action of both agents upon the myocardium, the concentration and volume of vasoconstrictor used, and the time since injection, when applicable, should be taken into account.
Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia. Because it is not known whether amide-type local anesthetics may trigger this reaction and because the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for management should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation. Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s), and institution of treatment, including oxygen therapy, indicated supportive measures, and dantrolene. (Consult dantrolene sodium intravenous package insert before using.)
Use in Head and Neck Area
Small doses of local anesthetics injected into the head and neck area may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. The injection procedures require the utmost care.
Confusion, convulsions, respiratory depression, and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded.
Information for Patients
When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of caudal or epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions listed in this package insert.
Clinically Significant Drug Interactions
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.
Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term studies in animals of most local anesthetics including mepivacaine to evaluate the carcinogenic potential have not been conducted. Mutagenic potential or the effect on fertility have not been determined. There is no evidence from human data that mepivacaine may be carcinogenic or mutagenic or that it impairs fertility.
Pregnancy Category C
Animal reproduction studies have not been conducted with mepivacaine. There are no adequate and well-controlled studies in pregnant women of the effect of mepivacaine on the developing fetus. Mepivacaine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. This does not preclude the use of mepivacaine at term for obstetrical anesthesia or analgesia.
Mepivacaine has been used for obstetrical analgesia by the epidural, caudal, and paracervical routes without evidence of adverse effects on the fetus when no more than the maximum safe dosages are used and strict adherence to technique is followed.
Labor and Delivery
Local anesthetics rapidly cross the placenta, and when used for epidural, paracervical, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity (see CLINICAL PHARMACOLOGY , Pharmacokinetics ). The incidence and degree of toxicity depend upon the procedure performed, the type and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function.
Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable.
Epidural, paracervical, caudal, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. In one study, paracervical block anesthesia was associated with a decrease in the mean duration of first stage labor and facilitation of cervical dilation. Epidural anesthesia has been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.
The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. The long-term significance of these observations is unknown.
Fetal bradycardia may occur in 20 to 30 percent of patients receiving para-cervical block anesthesia with the amide-type local anesthetics and may be associated with fetal acidosis. Fetal heart rate should always be monitored during paracervical anesthesia. Added risk appears to be present in prematurity, postmaturity, toxemia of pregnancy, and fetal distress. The physician should weigh the possible advantages against dangers when considering paracervical block in these conditions. Careful adherence to recommended dosage is of the utmost importance in obstetrical paracervical block. Failure to achieve adequate analgesia with recommended doses should arouse suspicion of intravascular or fetal intracranial injection.
Cases compatible with unintended fetal intracranial injection of local anesthetic solution have been reported following intended paracervical or pudendal block or both. Babies so affected present with unexplained neonatal depression at birth which correlates with high local anesthetic serum levels and usually manifest seizures within six hours. Prompt use of supportive measures combined with forced urinary excretion of the local anesthetic has been used successfully to manage this complication.
Case reports of maternal convulsions and cardiovascular collapse following use of some local anesthetics for paracervical block in early pregnancy (as anesthesia for elective abortion) suggest that systemic absorption under these circumstances may be rapid. The recommended maximum dose of the local anesthetic should not be exceeded. Injection should be made slowly and with frequent aspiration. Allow a five-minute interval between sides.
It is extremely important to avoid aortocaval compression by the gravid uterus during administration of regional block to parturients. To do this, the patient must be maintained in the left lateral decubitus position or a blanket roll or sandbag may be placed beneath the right hip and the gravid uterus displaced to the left.
Nursing Mothers
It is not known whether local anesthetic drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when local anesthetics are administered to a nursing woman.
Pediatric Use
Guidelines for the administration of mepivacaine to pediatric patients are presented in DOSAGE AND ADMINISTRATION .
Geriatric Use
Clinical studies and other reported clinical experience indicates that use of the drug in elderly patients requires a decreased dosage (see CLINICAL PHARMACOLOGY , PRECAUTIONS , General , and DOSAGE AND ADMINISTRATION ).
Mepivacaine and mepivacaine metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
ADVERSE REACTIONS:
Reactions to mepivacaine are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection, or slow metabolic degradation.
Systemic
The most commonly encountered acute adverse experiences which demand immediate countermeasures are related to the central nervous system and the cardiovascular system. These adverse experiences are generally dose related and due to high plasma levels which may result from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic dose-related toxicity, unintentional subarachnoid injection of drug during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column may result in underventilation or apnea (“Total or High Spinal”). Also, hypotension due to loss of sympathetic tone and respiratory paralysis or underventilation due to cephalad extension of the motor level of anesthesia may occur. This may lead to secondary cardiac arrest if untreated. Factors influencing plasma protein binding, such as acidosis, systemic diseases which alter protein production, or competition of other drugs for protein binding sites, may diminish individual tolerance.
Central Nervous System Reactions
These are characterized by excitation and/or depression. Restlessness, anxiety, dizziness, tinnitus, blurred vision, or tremors may occur, possibly proceeding to convulsions. However, excitement may be transient or absent, with depression being the first manifestation of an adverse reaction. This may quickly be followed by drowsiness merging into unconsciousness and respiratory arrest. Other central nervous system effects may be nausea, vomiting, chills, and constriction of the pupils.
The incidence of convulsions associated with the use of local anesthetics varies with the procedure used and the total dose administered. In a survey of studies of epidural anesthesia, overt toxicity progressing to convulsions occurred in approximately 0.1% of local anesthetic administrations.
Cardiovascular Reactions
High doses or, inadvertent intravascular injection, may lead to high plasma levels and related depression of the myocardium, decreased cardiac output, heart block, hypotension, bradycardia, ventricular arrhythmias, and possibly cardiac arrest (see WARNINGS , PRECAUTIONS , and OVERDOSAGE ).
Allergic
Allergic-type reactions are rare and may occur as a result of sensitivity to the local anesthetic or to other formulation ingredients, such as the antimicrobial preservative methylparaben, contained in multiple-dose vials. These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid-like symptomatology (including severe hypotension). Cross sensitivity among members of the amide-type local anesthetic group has been reported. The usefulness of screening for sensitivity has not been definitely established.
Neurologic
The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient. Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug.
In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter or needle may occur. Subsequent adverse effects may depend partially on the amount of drug administered intrathecally and the physiological and physical effects of a dural puncture. A high spinal is characterized by paralysis of the legs, loss of consciousness, respiratory paralysis, and bradycardia.
Neurologic effects following epidural or caudal anesthesia may include spinal block of varying magnitude (including high or total spinal block); hypotension secondary to spinal block; urinary retention; fecal and urinary incontinence; loss of perineal sensation and sexual function; persistent anesthesia, paresthesia, weakness, paralysis of the lower extremities, and loss of sphincter control all of which may have slow, incomplete, or no recovery; headache; backache; septic meningitis; meningismus; slowing of labor; increased incidence of forceps delivery; cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid.
Neurologic effects following other procedures or routes of administration may include persistent anesthesia, paresthesia, weakness, paralysis, all of which may have slow, incomplete or no recovery.
OVERDOSAGE:
Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution.
Management of Local Anesthetic Emergencies
The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.
If necessary, use drugs to control the convulsions. A 50 mg to 100 mg bolus IV injection of succinylcholine will paralyze the patient without depressing the central nervous or cardiovascular systems and facilitate ventilation. A bolus IV dose of 5 mg to 10 mg of diazepam or 50 mg to 100 mg of thiopental will permit ventilation and counteract central nervous system stimulation, but these drugs also depress central nervous system, respiratory, and cardiac function, add to postictal depression and may result in apnea. Intravenous barbiturates, anticonvulsant agents, or muscle relaxants should only be administered by those familiar with their use. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated. Supportive treatment of circulatory depression may require administration of intravenous fluids, and when appropriate, a vasopressor dictated by the clinical situation (such as ephedrine or epinephrine to enhance myocardial contractile force).
Endotracheal intubation, employing drugs and techniques familiar to the clinician may be indicated after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of patent airway or if prolonged ventilatory support (assisted or controlled) is indicated.
Recent clinical data from patients experiencing local anesthetic induced convulsions demonstrated rapid development of hypoxia, hypercarbia, and acidosis within a minute of the onset of convulsions. These observations suggest that oxygen consumption and carbon dioxide production are greatly increased during local anesthetic convulsions and emphasize the importance of immediate and effective ventilation with oxygen which may avoid cardiac arrest.
If not treated immediately, convulsions with simultaneous hypoxia, hypercarbia, and acidosis, plus myocardial depression from the direct effects of the local anesthetic may result in cardiac arrhythmias, bradycardia, asystole, ventricular fibrillation, or cardiac arrest. Respiratory abnormalities, including apnea, may occur. Underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted and maintained for a prolonged period if necessary. Recovery has been reported after prolonged resuscitative efforts.
The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus. Therefore, during treatment of systemic toxicity, maternal hypotension, or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible, or manual displacement of the uterus off the great vessels should be accomplished.
The mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 mcg/mL. The intravenous and subcutaneous LD50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.
DOSAGE AND ADMINISTRATION:
The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance and the physical condition of the patient. The smallest dose and concentration required to produce the desired result should be administered. Dosages of Mepivacaine Hydrochloride should be reduced for elderly and debilitated patients and patients with cardiac and/or liver disease. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional doses should be used when feasible.
For specific techniques and procedures, refer to standard textbooks.
The recommended single adult dose (or the total of a series of doses given in one procedure) of Mepivacaine Hydrochloride for unsedated, healthy, normal-sized individuals should not usually exceed 400 mg. The recommended dosage is based on requirements for the average adult and should be reduced for elderly or debilitated patients.
While maximum doses of 7 mg/kg (550 mg) have been administered without adverse effect, these are not recommended, except in exceptional circumstances and under no circumstances should the administration be repeated at intervals of less than 1½ hours. The total dose for any 24-hour period should not exceed 1,000 mg because of a slow accumulation of the anesthetic or its derivatives or slower than normal metabolic degradation or detoxification with repeat administration (see CLINICAL PHARMACOLOGY and PRECAUTIONS ).
Pediatric patients tolerate the local anesthetic as well as adults. However, the pediatric dose should be carefully measured as a percentage of the total adult dose based on weight, and should not exceed 5 mg/kg to 6 mg/kg (2.5 mg/lb to 3 mg/lb) in pediatric patients, especially those weighing less than 30 lbs. In pediatric patients under 3 years of age or weighing less than 30 lbs concentrations less than 2% (eg, 0.5% to 1.5%) should be employed.
Unused portions of solutions not containing preservatives, ie, those supplied in single-dose vials, should be discarded following initial use.
This product should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Solutions which are discolored or which contain particulate matter should not be administered.
Recommended Concentrations and Doses of Mepivacaine Hydrochloride
| Procedure | Concentration | mL | Total Dose | mg | Comments |
| Cervical, | 1% | 5-40 | | 50-400 | Pudendal block: |
| brachial, | | | | | one half of total |
| | | | | | |
| intercostal, | | | | | dose injected |
| | | | | | |
| pudendal | 2% | 5-20 | | 100-400 | each side. |
| | | | | | |
| nerve block | | | | | |
| Transvaginal | 1% | up to 30 | | up to 300 | One half of total |
| block | | (both sides) | | (both sides) | dose injected |
| | | | | | |
| (paracervical | | | | | each side. See |
| | | | | | |
| plus pudendal) | | | | | PRECAUTIONS. |
| Paracervical | 1% | up to 20 | | up to 200 | One half of total |
| block | | (both sides) | | (both sides) | dose injected each |
| | | | | | |
| | | | | | side. This is maxi- |
| | | | | | |
| | | | | | mum recommended |
| | | | | | |
| | | | | | dose per 90-minute |
| | | | | | |
| | | | | | period in obstetrical |
| | | | | | |
| | | | | | and non-obstetrical |
| | | | | | |
| | | | | | patients. Inject slowly, |
| | | | | | |
| | | | | | 5 minutes between |
| | | | | | |
| | | | | | sides. See |
| | | | | | |
| | | | | | PRECAUTIONS. |
| Caudal and | 1% | 15-30 | | 150-300 | *Use only single-dose |
| Epidural block | 1.5% | 10-25 | | 150-375 | vials which do not |
| | | | | | |
| | 2% | 10-20 | | 200-400 | contain a preservative. |
| Infiltration | 1% | up to 40 | | up to 400 | An equivalent amount |
| | | | | | of a 0.5% solution |
| | | | | | |
| | | | | | (prepared by diluting |
| | | | | | |
| | | | | | the 1% solution with |
| | | | | | |
| | | | | | Sodium Chloride |
| | | | | | |
| | | | | | Injection, USP) may |
| | | | | | |
| | | | | | be used for large |
| | | | | | |
| | | | | | areas. |
| Therapeutic | 1% | 1-5 | | 10-50 | |
| block (pain | 2% | 1-5 | | 20-100 | |
| | | | | | |
| management) | | | | | |
| | | | | | |
| Unused portions of solutions not containing preservatives should be discarded. | |||||
* Dosage forms listed as POLOCAINE-MPF (Mepivacaine HCl Injection, USP) are single-dose solutions which do not contain a preservative.
HOW SUPPLIED:
Single-dose vials and multiple-dose vials of Mepivacaine Hydrochloride may be sterilized by autoclaving at 15 pound pressure, 121°C (250°F) for 15 minutes. Solutions of Mepivacaine Hydrochloride may be reautoclaved when necessary. Do not administer solutions which are discolored or which contain particulate matter.
THESE SOLUTIONS ARE NOT INTENDED FOR SPINAL ANESTHESIA OR DENTAL USE.
POLOCAINE-MPF (Mepivacaine HCl Injection, USP) without preservatives is available as follows:
| Product No. | NDC No. | Strength | Vial Size |
| 261030 | 63323-260-30 | 1% (10 mg/mL) | 30 mL single dose vial, packaged individually. |
| 293030 | 63323-293-30 | 1.5% (15 mg/mL) | 30 mL single dose vial, packaged individually. |
| 294020 | 63323-294-20 | 2% (20 mg/mL) | 20 mL single dose vial, packaged individually. |
Mepivacaine Hydrochloride (mepivacaine HCl Injection, USP) with preservatives is available as follows:
| Product No. | NDC No. | Strength | Vial Size |
| 283050 | 63323-283-50 | 1% (10 mg/mL) | 50 mL multiple dose vial, packaged individually. |
| 296050 | 63323-296-50 | 2% (20 mg/mL) | 50 mL multiple dose vial, packaged individually. |
Store at 20° to 25°C (68° to 77°F) ; brief exposure up to 40°C (104°F) does not adversely affect the product.
All trademarks are the property of APP Pharmaceuticals, LLC.
Manufactured for:
451105A/Revised: May 2008
APP Address Band Logo
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine-MPF 30 mL Single Dose Vial Carton Panel
NDC 63323-260-30
261030
Mepivacaine Hydrochloride ® -MPF
(mepivacaine HCl Injection, USP)
1%
10 mg/mL
For Nerve Block, Caudal, Epidural and Infiltration Anesthesia.
Not Intended for Spinal Anesthesia or Dental Use.
Methylparaben Free
Rx only
30 mL Single Dose Vial
DISPLAY PANEL - Polocaine-MPF 30 mL Single Dose Vial Carton
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine-MPF 30 mL Single Dose Vial Label
NDC 63323-260-30
261030
Mepivacaine Hydrochloride ® -MPF
(mepivacaine HCl Injection, USP)
1% (10 mg/mL)
For Nerve Block, Caudal, Epidural and Infiltration Anesthesia.
Not Intended for Spinal Anesthesia or Dental Use.
Methylparaben Free
30 mL Single Dose Vial
DISPLAY PANEL - Polocaine-MPF 30 mL Single Dose Vial
NDC 63323-283-50
283050
Mepivacaine Hydrochloride ®
(mepivacaine HCl Injection, USP)
1%
10 mg/mL
For Infiltration and Nerve Block Only
Not Intended for Spinal Anesthesia or Dental Use.
Rx only
50 mL Multiple Dose Vial
DISPLAY PANEL - Mepivacaine Hydrochloride 50 mL Multiple Dose Vial Carton
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine 50 mL Multiple Dose Vial Label
NDC 63323-283-50
283050
Mepivacaine Hydrochloride ®
(mepivacaine HCl Injection, USP)
1% (10 mg/mL)
For Infiltration and Nerve Block Only.
Not Intended for Spinal Anesthesia or Dental Use.
50 mL Multiple Dose Vial
DISPLAY PANEL - Mepivacaine Hydrochloride 50 mL Multiple Dose Vial
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine-MPF 30 mL Single Dose Vial Carton Panel
NDC 63323-293-30
293030
(mepivacaine HCl Injection, USP)
1.5%
15 mg/mL
For Nerve Block, Caudal, Epidural and Infiltration Anesthesia.
Not Intended for Spinal Anesthesia or Dental Use.
Methylparaben Free
Rx only
30 mL Single Dose Vial
DISPLAY PANEL - Polocaine-MPF 30 mL Single Dose Vial Carton
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine-MPF 30 mL Single Dose Vial Label
NDC 63323-293-30
293030
(mepivacaine HCl Injection, USP)
1.5% (15 mg/mL)
For Nerve Block, Caudal, Epidural and Infiltration Anesthesia.
Not Intended for Spinal Anesthesia or Dental Use.
Methylparaben Free
30 mL Single Dose Vial
DISPLAY PANEL - Polocaine-MPF 30 mL Single Dose Vial
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine-MPF 20 mL Single Dose Vial Carton Panel
NDC 63323-294-20
294020
(mepivacaine HCl Injection, USP)
2%
20 mg/mL
For Nerve Block, Caudal, Epidural and Infiltration Anesthesia.
Not Intended for Spinal Anesthesia or Dental Use.
Methylparaben Free
Rx only
20 mL Single Dose Vial
DISPLAY PANEL - Polocaine-MPF 20 mL Single Dose Vial Carton
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine-MPF 20 mL Single Dose Vial Label
NDC 63323-294-20
294020
(mepivacaine HCl Injection, USP)
2% (20 mg/mL)
For Nerve Block, Caudal, Epidural and Infiltration Anesthesia.
Not Intended for Spinal Anesthesia or Dental Use.
Methylparaben Free
20 mL Single Dose Vial
DISPLAY PANEL - Polocaine-MPF 20 mL Single Dose Vial
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine 50 mL Multiple Dose Vial Carton Panel
NDC 63323-296-50
296050
Mepivacaine Hydrochloride ®
(mepivacaine HCl Injection, USP)
2%
20 mg/mL
For Infiltration and Nerve Block Only.
Not Intended for Spinal Anesthesia or Dental Use.
Rx only
50 mL Multiple Dose Vial
DISPLAY PANEL - Mepivacaine Hydrochloride 50 mL Multiple Dose Vial Carton
PACKAGE LABEL - PRINCIPAL DISPLAY - Polocaine 50 mL Multiple Dose Vial Label
NDC 63323-296-50
296050
Mepivacaine Hydrochloride ®
(mepivacaine HCl Injection, USP)
2% (20 mg/mL)
For Infiltration and Nerve Block Only.
Not Intended for Spinal Anesthesia or Dental Use.
50 mL Multiple Dose Vial
DISPLAY PANEL - Mepivacaine Hydrochloride 50 mL Multiple Dose Vial
Mepivacaine Hydrochloride available forms, composition, doses:
Indications and Usages:
ATC codes:
ICD-10 codes:
Mepivacaine Hydrochloride destination | category:
Drugs with same active ingredients (Pharmaceutical companies):
References
- Dailymed."POLOCAINE (MEPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION POLOCAINE-MPF (MEPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [APP PHARMACEUTICALS, LLC]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- "mepivacaine". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
- "mepivacaine". http://www.drugbank.ca/drugs/DB0096... (accessed August 28, 2018).
Frequently asked Questions
Can i drive or operate heavy machine after consuming Mepivacaine Hydrochloride?Depending on the reaction of the Mepivacaine Hydrochloride after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Mepivacaine Hydrochloride not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Mepivacaine Hydrochloride addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Review
sdrugs.com conducted a study on Mepivacaine Hydrochloride, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Mepivacaine Hydrochloride consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.Visitor reports
Visitor reported useful
No survey data has been collected yetVisitor reported side effects
No survey data has been collected yetVisitor reported price estimates
No survey data has been collected yetVisitor reported frequency of use
No survey data has been collected yetVisitor reported doses
No survey data has been collected yetVisitor reported time for results
No survey data has been collected yetVisitor reported administration
No survey data has been collected yetVisitor reported age
No survey data has been collected yetVisitor reviews
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology